This comprehensive review synthesizes current knowledge across the full spectrum of AD, encompassing molecular pathophysiology (amyloid cascade, tau hyperphosphorylation, and neuroinflammation), genetic architecture, genetic architecture (familial mutations and APOE-mediated risk), evolving biomarker-based diagnostic f...
Azzam Zrineh, Rami Akwan, Roaa Darawsheh et al.· 0 citations
Low-density lipoprotein cholesterol (LDL-C) is the principal target for preventing atherosclerotic cardiovascular disease, yet many patients do not reach treatment goals with statins, and established proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies require injections every 2-4 weeks. Recaticimab is a hu...
Ahmed Talkhan, Amr M. Abou Elezz, N. Borham et al.· Cardiology in Review· 0 citations
Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9 that reduces LDL-C and increases apolipoprotein A1 and high-density lipoprotein cholesterol and increased apolipoprotein A1 and high-density lipoprotein cholesterol (all P < 0.0001).
Ahmed Talkhan, M. Elkasaby, Ahmed S. A. Osman et al.· Cardiology in Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.